Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Aptinyx Inc (APTX)
Aptinyx Inc (APTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,835
  • Shares Outstanding, K 67,716
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,850 K
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.26
Trade APTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.98
  • Most Recent Earnings -0.31 on 05/18/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 216.11%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,097.15% on 12/12/22
  • IV Low 0.00% on 05/24/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 769
  • Open Int (30-Day) 835

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +80.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0500 +42.80%
on 05/19/23
0.1280 -44.22%
on 05/03/23
-0.0522 (-42.23%)
since 04/26/23
3-Month
0.0500 +42.80%
on 05/19/23
0.6000 -88.10%
on 02/27/23
-0.5006 (-87.52%)
since 02/24/23
52-Week
0.0500 +42.80%
on 05/19/23
0.7390 -90.34%
on 07/08/22
-0.4278 (-85.70%)
since 05/26/22

Most Recent Stories

More News
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up

Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus....

BMY : 63.82 (-1.15%)
ADMA : 4.08 (+3.55%)
EDIT : 9.10 (+0.22%)
APTX : 0.0714 (-0.83%)
McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

MCK : 387.95 (-1.88%)
PKI : 115.24 (-0.91%)
APTX : 0.0714 (-0.83%)
BRBR : 36.84 (+0.74%)
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

REGN : 725.05 (+0.01%)
RARE : 49.83 (-0.18%)
APTX : 0.0714 (-0.83%)
ETNB : 17.69 (+6.89%)
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

RHHBY : 40.2600 (+0.90%)
ADMA : 4.08 (+3.55%)
BPMC : 57.75 (+6.39%)
APTX : 0.0714 (-0.83%)
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.

DVA : 94.28 (-0.82%)
APTX : 0.0714 (-0.83%)
BRBR : 36.84 (+0.74%)
SRZN : 0.6479 (+7.98%)
Novo Nordisk (NVO) Q1 Earnings In Line, Sales Miss, View Up

Novo Nordisk (NVO) reports decent first-quarter results as earnings match estimates but sales miss the same. Sales benefit from growth in Diabetes and Obesity Care on higher GLP-1 and Wegovy revenues.

SNY : 52.51 (-0.15%)
NVO : 162.97 (+0.33%)
ADMA : 4.08 (+3.55%)
APTX : 0.0714 (-0.83%)
Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss

Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.

PFE : 37.60 (-0.61%)
ADMA : 4.08 (+3.55%)
DCPH : 13.79 (-1.50%)
APTX : 0.0714 (-0.83%)
Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

AMGN : 216.93 (-0.24%)
HZNP : 99.61 (-0.27%)
ADMA : 4.08 (+3.55%)
APTX : 0.0714 (-0.83%)
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

ITCI : 60.20 (+0.05%)
ACAD : 24.78 (+1.35%)
AXSM : 69.80 (+2.51%)
APTX : 0.0714 (-0.83%)
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK

Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.

GSK : 34.24 (+0.38%)
ACAD : 24.78 (+1.35%)
APTX : 0.0714 (-0.83%)
BLU : 14.56 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0806
2nd Resistance Point 0.0782
1st Resistance Point 0.0748
Last Price 0.0714
1st Support Level 0.0690
2nd Support Level 0.0666
3rd Support Level 0.0632

See More

52-Week High 0.7390
Fibonacci 61.8% 0.4758
Fibonacci 50% 0.3945
Fibonacci 38.2% 0.3132
Last Price 0.0714
52-Week Low 0.0500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar